Drug
Dihydroergotamine clinical trials
Also written MAP0004.
- studies test it
- 13
- open now
- 0
- in phase 3
- 4
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 2
- Phase 3
- 4
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 3
Satsuma Pharmaceuticals, Inc. (5) · Allergan (4) · Thomas Jefferson University (2) · Pulmatrix Inc. (1) · Kimberly S Jones (1)
Often tested with
Tested in the same studies.
PUR3100 (1) · Ketoconazole (1) · Valproic Acid (1)
Studies
Open first, then newest update. How each study uses Dihydroergotamine is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of MigraineCompletedPhase 3Satsuma Pharmaceuticals, Inc.NCT04940390Written as Dihydroergotamine
- A Study to Evaluate the Safety of STS101 in the Acute Treatment of MigraineCompletedPhase 3Satsuma Pharmaceuticals, Inc.NCT04406649Written as Dihydroergotamine
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of MigraineCompletedPhase 3Satsuma Pharmaceuticals, Inc.NCT03901482Written as Dihydroergotamine
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health AdultsCompletedPhase 1Pulmatrix Inc.NCT05351086Written as Dihydroergotamine (D.H.E 45)
- A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy SubjectsCompletedPhase 1Satsuma Pharmaceuticals, Inc.NCT05337254Written as Dihydroergotamine
- A Research Study Examining Migranal and Skin Sensitivity in Subjects With MigraineCompletedPhase 4Thomas Jefferson UniversityNCT00335777Written as Migranal nasal spray at 1 hour
- Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric MigraineTerminatedPhase 2Kimberly S JonesNCT03885154Written as Dihydroergotamine (DHE)
- A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy SubjectsCompletedPhase 1Satsuma Pharmaceuticals, Inc.NCT03874832Written as Dihydroergotamine
- A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin SensitivityCompletedNot applicableThomas Jefferson UniversityNCT00203268Written as dihydroergotamine mesylate
- Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult VolunteersCompletedPhase 1/2AllerganNCT01199965Written as MAP0004
- Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial PressureCompletedPhase 1AllerganNCT01089062Written as MAP0004
- Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With KetoconazoleCompletedPhase 1AllerganNCT01468558Written as MAP0004
- Phase 3 Study of MAP0004 in Adult MigraineursCompletedPhase 3AllerganNCT00623636Written as MAP0004
Given in every arm · 1 — Dihydroergotamine is usual care beside what is tested
As the comparator · 2 — what is tested is compared with Dihydroergotamine
- A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy AdultsCompletedPhase 1Aspeya Switzerland SANCT07226362Written as DHE 2 mg administered by nasal spray (Migranal®)
- Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy AdultsCompletedPhase 1Impel PharmaceuticalsNCT03401346Written as Dihydroergotamine Mesylate (DHE)
Codes
What other systems call Dihydroergotamine · ClinicalTrials.gg INT007355
- MeSH (NLM) D004087DihydroergotamineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 436O5HM03CDIHYDROERGOTAMINEConfirmed FDA, NLM, Wikidata
- RxNorm 3418Confirmed FDA, Wikidata
- Wikidata Q421336dihydroergotamineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65387DihydroergotamineOne source FDA
- DrugBank DB00320One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D004087 | Dihydroergotamine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 436O5HM03C | DIHYDROERGOTAMINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3418 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421336 | dihydroergotamine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65387 | Dihydroergotamine | One source FDA |
| DrugBank | DB00320 | — | One source Wikidata |
Also registered as dihydroergotamine mesylate (UNII 81AXN7R2QT · RxNorm 203176).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.